HIGHLIGHTS
SUMMARY
The greatest benefit was observed in patients with a tumoral programmed cell death 1 ligand 1 (PD-L1) expression ≥1%7. The few patients who had received gemcitabine and had available paired samples (n=2) showed PD-L1-upregulation despite the lack of neoadjuvant radiotherapy, and only 3/11 cases were PD-L1 negative in the resection specimens. The prognostic power of PD-L1 expression as a double-edged sword has already been described exhaustively in advanced NSCLC and a high PD-L1 expression does not seem to be consistently associated with shorter survival42 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.